Identification of pathways involved in paclitaxel activity in cervical cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 1, 2011, Pages 99-102

  Qiao, Wen Juan ^a   Cheng, Hai Yan ^a   Li, Chun Quan ^a   Jin, Hong ^a   Yang, Shan Shan ^a   Li, Xia ^a   Zhang, Yun Yan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Cervical cancer; Paclitaxel; Resistance; Signaling pathway

Indexed keywords

EID: 79958723419     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Abdel Salam I, Gaballa HE, Abdel Wahab N. (2009). Serum levels of epidermal growth factor and HER-2 neu in non small-cell lung cancer: prognostic correlation. Med Oncol, 26, 161-6.
2. Biewenga P, Buist MR, Moerland PD, et al. (2008). Gene expression in early stage cervical cancer. Gynecol Oncol, 108, 520-6.
3. de Graeff P, Crijns AP, Ten Hoor KA, et al. (2008). The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer, 99, 341-9.
4. Feng Z Hu W, de Stanchina E, Teresky A, et al. (2007). The regulation of AMPK β1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Cancer Res, 67, 3043.
5. Feng Z, Zhang H, Levine AJ, et al. (2005). The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci U S A, 102, 8204-9.
6. Gogas H, Pectasides D, Kostopoulos I, et al. (2010). Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: a phase II trial of the hellenic cooperative oncology group. Clin Breast Cancerr, 10, 230-7.
7. Greenfield C, Hiles I, Waterfield MD, et al. (1989). Epidermal growth factor binding induces a conformational change in the external domain of its receptor. EMBO J, 8, 4115-23.
8. Hogberg T. (2010). Chemotherapy: Current drugs still have potential in advanced ovarian cancer. Nat Rev Clin Oncol, 7, 191-3.
9. Idirisinghe PK, Thike, AA, Cheok PY, et al. (2010). Hormone receptor and c-ERBB2 status in distant metastatic and locally recurrent breast cancer. Pathologic correlations and clinical significance. Am J Clin Pathol, 133, 416-29.
10. Kanehisa M, Goto S, Hattori M, et al. (2006). From genomics to chemical genomics: new developments in KEGG. Nucleic Acids Res, 34, D354-7.
11. Kim JH, Lee KW, Kim YH, et al. (2010). Individualized tumor response testing for prediction of response to Paclitaxel and Cisplatin chemotherapy in patients with advanced gastric cancer. J Korean Med Sci, 25, 684-90.
12. Komuta K, Osaki T, Mori M, et al. (2010). A phase II study directed by a clinical pathway for carboplatin and weekly paclitaxel in previously untreated patients with unresectable non-small cell lung cancer. Chemotherapy, 56, 39-45.
13. Kunz C, Borghouts C, Buerger C, et al. (2006). Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol. Mol Cancer Res, 4, 983-98.
14. Li C, Li X, Miao Y, et al. (2009). SubpathwayMiner: a software package for flexible identification of pathways. Nucleic Acids Res, 37, e131.
15. Nicholson KM, Anderson NG. (2002). The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal, 14, 381-95.
16. Park DC, Suh MJ, Yeo SG. (2009). Neoadjuvant paclitaxel and cisplatin in uterine cervical cancer: long-term results. Int J Gynecol Cancer, 19, 943-7.
17. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659-72.
18. Pryczynicz A, Guzinska-Ustymowicz K, Kemona A, et al. (2009). Helicobacter pylori infection and expressions of EGF, EGFR and c-erbB-2 proteins in gastric carcinoma. Folia Histochem Cytobiol, 47, 447-51.
19. Rajkumar T, Vijayalakshmi N, Sabitha K, et al. (2009). A 7 gene expression score predicts for radiation response in cancer cervix. BMC Cancer, 9, 365.
20. Romond EH, Perez EA, Bryant J, et al. (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84.
21. Saito I, Kitagawa R, Fukuda H, et al. (2010). A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol, 40, 90-3.
22. Scotto L, Narayan G, Nandula SV, et al. (2008). Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression. Genes Chromosomes Cancer, 47, 755-65.
23. Seidman R, Gitelman I, Sagi O, et al. (2001). The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ovarian carcinoma cells. Exp Cell Res, 268, 84-92.
24. Simonetti S, Russo R, Ciancia G, et al. (2009). Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol, 17, 198-205.
25. Yang SH, Sharrocks AD, Whitmarsh AJ. (2003). Transcriptional regulation by the MAP kinase signaling cascades. Gene, 320, 3-21.
26. Yarden Y, Schlessinger J. (1987). Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry, 26, 1443-51.